Long-term follow-up of a large active surveillance cohort of patients with prostate cancer

Journal of Clinical Oncology

Volumn 33, Issue 3, 2015, Pages 272-277

  Klotz, Laurence ^a   Vesprini, Danny ^a   Sethukavalan, Perakaa ^a   Jethava, Vibhuti ^a   Zhang, Liying ^a   Jain, Suneil ^a   Yamamoto, Toshihiro ^a   Mamedov, Alexandre ^a   Loblaw, Andrew ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER MORTALITY; CANCER PATIENT; CANCER RISK; CANCER SURVIVAL; CANCER SURVIVOR; CAUSE SPECIFIC SURVIVAL; COHORT ANALYSIS; DISEASE SPECIFIC SURVIVAL; DISEASE SURVEILLANCE; FOLLOW UP; GLEASON SCORE; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; OVERALL SURVIVAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE BIOPSY; PROSTATE CANCER; TUMOR BIOPSY; VERY ELDERLY; BLOOD; CANADA; CANCER GRADING; DISEASE FREE SURVIVAL; EPIDEMIOLOGY; HEALTH SURVEY; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; PATHOLOGY; PROCEDURES; PROSTATIC NEOPLASMS; RISK; RISK FACTOR; TIME; WATCHFUL WAITING;

AGED; AGED, 80 AND OVER; DISEASE-FREE SURVIVAL; FOLLOW-UP STUDIES; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOPLASM GRADING; ODDS RATIO; ONTARIO; POPULATION SURVEILLANCE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RISK FACTORS; TIME FACTORS; TUMOR MARKERS, BIOLOGICAL; WATCHFUL WAITING;

EID: 84921755394     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2014.55.1192     Document Type: Article

References (18)

1. Choo R, Klotz L, Danjoux C, et al: Feasibility study: Watchful waiting for localized low to intermediate grade prostate carcinoma with selective delayed intervention based on prostate specific antigen, histological and/or clinical progression. J Urol 167:1664-1669, 2002
2. Klotz L: Active surveillance for prostate cancer: For whom? J Clin Oncol 23:8165-8169, 2005
3. Klotz L, Zhang L, Lam A, et al: Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. J Clin Oncol 28:126-131, 2010
4. Remzi M, Fong YK, Dobrovits M, et al: The Vienna nomogram: Validation of a novel biopsy strategy defining the optimal number of cores based on patient age and total prostate volume. J Urol 174:1256-1260, 2005
5. Altman DG, De Stavola BL, Love SB, et al: Review of survival analyses published in cancer journals. Br J Cancer 72:511-518, 1995
6. Zhang L, Loblaw A, Klotz L: Modeling prostate specific antigen kinetics in patients on active surveillance. J Urol 176:1392-1397, 2006
7. Albertsen PC, Hanley JA, Fine J: 20-year outcomes following conservative management of clinically localized prostate cancer. JAMA 293:2095-2101, 2005
8. van As NJ, Norman AR, Thomas K, et al: Predicting the probability of deferred radical treatment for localised prostate cancer managed by active surveillance. Eur Urol 54:1297-1305, 2008
9. Carter HB, Kettermann A, Warlick C, et al: Expectant management of prostate cancer with curative intent: An update of the Johns Hopkins experience. J Urol 178:2359-2364, 2007
10. Soloway MS, Soloway CT, Williams S, et al: Active surveillance: A reasonable management alternative for patients with prostate cancer - The Miami experience. BJU Int 101:165-169, 2008
11. Roemeling S, Roobol MJ, de Vries SH, et al: Active surveillance for prostate cancers detected in three subsequent rounds of a screening trial: Characteristics, PSA doubling times, and outcome. Eur Urol 51:1244-1250, 2007
12. Khatami A, Aus G, Damber JE, et al: PSA doubling time predicts the outcome after active surveillance in screening-detected prostate cancer: Results from the European randomized study of screening for prostate cancer, Sweden section. Int J Cancer 120:170-174, 2007
13. Popiolek M, Rider JR, Ondren O, et al: Natural history of early localized prostate cancer: A final report from three decades of follow up. Eur Urol 63:428-435, 2013
14. Vickers AJ, Savage C, O'Brien MF, et al: Systematic review of pretreatment prostate-specific antigen velocity and doubling time as predictors for prostate cancer. J Clin Oncol 27: 398-403, 2009
15. Loblaw A, Zhang L, Lam A, et al: Comparing prostate specific antigen triggers for intervention in men with stable prostate cancer on active surveillance. J Urol 184:1942-1946, 2010
16. Kane CJ, Im R, Amling CL, et al: Outcomes after radical prostatectomy among men who are candidates for active surveillance: Results from the SEARCH database. Urology 76:695-700, 2010
17. Lukka H, Hayter C, Julian JA, et al: Randomized trial comparing two fractionation schedules for patients with localized prostate cancer. J Clin Oncol 23:6132-6138, 2005
18. Efron B: Bootstrap methods: Another look at the jackknife. Ann Statist 7:1-26, 1979